Aptevo Therapeutics Q3 2026 net loss narrows 13% year over year to $6.5 million
APVO•Aptevo Therapeutics’ third-quarter 2026 net loss narrowed 13% year over year to $6.5 million, while cash and cash equivalents fell 15% from June 30 to $8.3 million at September 30. The company reported a 79% remission rate among 14 evaluable patients in a mipletamig combination study.
1. Quarterly results and cash
Aptevo Therapeutics’ third-quarter 2026 net loss narrowed 13% year over year to $6.5 million. Cash and cash equivalents were $8.3 million at September 30, down 15% from June 30. An August warrant inducement and private placement generated approximately $4.5 million in gross proceeds.
2. Trial results and timeline
Mipletamig combined with venetoclax and azacitidine achieved a 79% remission rate among 14 evaluable patients with TP53-mutated AML. Aptevo targets completion of RAINIER Phase 1b dose optimization by year-end 2026 and plans regulatory interaction in the first half of 2027.




